免疫检查点抑制剂淋巴细胞活化基因-3在淋巴瘤免疫治疗中的研究进展

Research progress of immune checkpoint lymphocyte activation gene-3 in lymphoma immunotherapy

免疫检查点抑制剂的阻断治疗推动了免疫肿瘤学领域的发展,改善了某些实体肿瘤和血液肿瘤患者的临床结局。淋巴细胞活化基因-3(LAG-3)是一种免疫检查点受体蛋白,存在于活化的T细胞表面,能与抗原呈递细胞(APCs)上的主要组织相容性复合体Ⅱ(MHCⅡ)结合,抑制细胞增殖和T细胞活化,对免疫逃逸发挥作用,或许可能成为淋巴瘤免疫治疗中有前景的靶点。本文综述了LAG-3的结构、作用机制在不同淋巴瘤中的表达及目前的LAG-3阻滞剂。

Blockade therapy at immune checkpoint inhibitor has advanced the field of immuno-oncology,improving clinical outcomes for patients with certain solid tumors and hematological tumors.Lymphocyte activation gene-3(LAG-3)is an immune checkpoint receptor protein that exists on the surface of activated T cells and can bind to major histocompatibility complex classⅡ(MHCⅡ)on antigen-presenting cells(APCs),inhibit cell proliferation and T cell activation,and play a role in immune escape,which may be a promising target in lymphoma immunotherapy.This article reviews the structure,mechanism of action of LAG-3 expression in different lymphomas and current LAG-3 blockers.